Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
155.8 USD | -0.72% | +25.57% | +60.82% |
06-26 | Monetary policy is getting even more confusing | |
06-26 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.82% | 14.83B | |
+16.79% | 122B | |
+19.81% | 115B | |
+21.22% | 26.64B | |
-23.17% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.64% | 15.49B | |
+3.35% | 13.67B | |
+118.44% | 11.12B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket